• Ertugliflozin Mitigates Tau Pathology via Brain Insulin Modu

  2026-05-26

  The reference study demonstrates that Ertugliflozin, a selective SGLT2 inhibitor, alleviates cognitive impairment and reduces tau hyperphosphorylation in a rat model of Alzheimer's disease by restoring disrupted brain insulin signaling. These findings highlight a novel mechanistic link between SGLT2 inhibition and neuroprotection, expanding the therapeutic potential of Ertugliflozin beyond diabetes research.

• Canagliflozin Hemihydrate: Research-Grade SGLT2 Inhibitor In

  2026-05-26

  Explore the advanced scientific principles and research applications of Canagliflozin hemihydrate, a high-purity SGLT2 inhibitor, with in-depth analysis of its assay specificity and protocol optimization. This article uniquely examines practical assay decisions in light of cutting-edge mTOR pathway screening technologies.

• Protease Inhibitor Cocktail (EDTA-Free, 100X): Actionable Gu

  2026-05-25

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) prevents unwanted proteolysis during protein extraction and sample preparation, especially for workflows where divalent cations must be preserved. It is suitable for Western blotting, co-immunoprecipitation, and phosphorylation-sensitive assays, but is not intended for protocols requiring metalloprotease inhibition via EDTA.

• Ferroptosis Gene Signature and Atorvastatin in HCC Prognosis

  2026-05-25

  This study defines a novel ferroptosis-related gene signature for prognostication in hepatocellular carcinoma (HCC) and identifies atorvastatin as a potential agent to induce ferroptosis in HCC cells. The findings provide both a validated bioinformatic tool for risk stratification and experimental evidence supporting HMG-CoA reductase inhibitors in ferroptosis-based therapy.

• JC-1 Fluorescent Probe: Precision Mitochondrial Assays Unloc

  2026-05-24

  JC-1 empowers researchers to decode mitochondrial health with ratiometric, real-time precision, enabling robust apoptosis detection and cellular bioenergetics studies. This guide delivers optimized workflows, troubleshooting insights, and actionable protocol parameters to maximize JC-1’s translational impact across cancer and metabolic research.

• Light and Brassinolide Independently Regulate Arabidopsis Ro

  2026-05-23

  This study demonstrates that light and brassinosteroids (BRs), including brassinolide, modulate Arabidopsis seedling root growth largely via independent pathways. The findings clarify that both endogenous and exogenous BRs act as suppressors of root elongation, regardless of light conditions, redefining the established understanding of BR-light signaling interplay in early plant development.

• Brassinolide: Applied Protocols for Plant and Biomedical Res

  2026-05-22

  Brassinolide (24-Epibrassinolide) stands out as a dual-domain tool, optimizing both plant growth assays and translational cancer or diabetes workflows. This guide delivers actionable protocols, comparative insights, and troubleshooting strategies to help researchers leverage Brassinolide’s full potential.

• Lipid Peroxidation (MDA) Assay Kit: Precision in Oxidative S

  2026-05-22

  The Lipid Peroxidation (MDA) Assay Kit delivers unmatched sensitivity and reproducibility for malondialdehyde quantification in diverse biological samples. Its dual-mode colorimetric and fluorescence detection streamlines workflows in oxidative stress and ferroptosis research, directly supporting translational studies on drug resistance mechanisms.

• SGLT2 Inhibitors in Cardiac Ischemia: Class Effects and Drug

  2026-05-21

  This study rigorously compared three selective SGLT2 inhibitors—empagliflozin, dapagliflozin, and ertugliflozin—in a non-diabetic mouse model of myocardial ischemia/reperfusion injury. The research revealed that only empagliflozin and dapagliflozin, but not ertugliflozin at standard dosing, significantly reduced infarct size, indicating that cardioprotection in this context is drug-specific and not a uniform class effect.

• Troglitazone as a PPARγ Agonist: Workflows for Diabetes & On

  2026-05-21

  Troglitazone, a dual PPARγ/α agonist, empowers researchers to dissect lipid and glucose metabolism as well as tumor microenvironment pathways in both type 2 diabetes and oncology models. This article delivers actionable protocols, advanced troubleshooting, and translates key findings on immune modulation for maximal translational impact.

• AIBP-LRP2–HDL Axis Limits CXCR4+ Capillary Expansion in Isch

  2026-05-20

  This study elucidates a novel regulatory pathway in which AIBP and LRP2 mediate endothelial HDL uptake to suppress CXCR4+ stemlike capillary endothelial cell expansion, thereby restricting collateral circulation in ischemic disease. These findings clarify the two-phase process of vascular remodeling and highlight new targets for therapeutic revascularization.

• Anagliptin (SK-0403): Mechanistic Leverage in Vascular Diabe

  2026-05-20

  This article explores the dual mechanistic action of Anagliptin (SK-0403) as a DPP-4 inhibitor with direct vasorelaxant effects via Kv channels and SERCA pump activation, offering strategic guidance for translational researchers targeting diabetes and cardiovascular comorbidities.

• Sulfo-Cy3 NHS Ester: Advanced Probe Engineering for Protein

  2026-05-19

  Explore the scientific principles and unique applications of Sulfo-Cy3 NHS Ester, a hydrophilic fluorescent dye engineered for robust protein labeling. This article delivers an in-depth analysis, bridging latest vascular biology research with advanced assay design.

• Tetrahydromagnolol: Redefining CB2 Agonist Use in Metastatic

  2026-05-19

  Explore how tetrahydromagnolol, a potent peripheral CB2 receptor agonist, is transforming advanced cannabinoid receptor research. This article uniquely details its mechanistic advantages, protocol parameters, and specific value in metastatic GPCR signaling models.

• Lipid Scrambling in Ferroptosis: TMEM16F as a Tumor Immune G

  2026-05-18

  Yang et al. uncover TMEM16F-mediated lipid scrambling as a critical suppressor of ferroptosis, revealing how its disruption triggers tumor cell death and enhances immune rejection. This mechanistic insight reframes the plasma membrane as a key site of regulation in programmed necrosis, with implications for cancer therapy and immune modulation.

8139 records 14/543 page Previous Next First page 上5页 1112131415 下5页 Last page